Decision-Making and Process
The Truth about Teams
When it comes to team performance and adherence to “best practices,” what works on paper or in a teambuilding workshop and what actually occurs are often two very different things. Not for lack of trying (in most cases!), the practical constraints of time, resources, and human nature often get in the way. Fortunately, there are approaches to… Read the full article… |
Patient Advocacy – Delivering on Patient Centricity in Drug Development
Historically, biopharma companies developed drugs for patients with an illness — but the illness was the primary focus. In recent years, much has changed. As drug development has become more enlightened, understanding the experience of people living with health conditions — their needs, goals, and the practicalities of daily life — has become integral to the process of… Read the full article… |
Beyond the One-Hit Wonder
Innovation in our industry is extraordinary on so many levels. The science is unparalleled, the collective intellect is exceptional, and the passion for the patient is unwavering. Mobilizing this innovation to discover, develop, and commercialize novel treatments for patients, all while building a company, can be a Herculean task. When we work with emerging companies, we… Read the full article… |
Optimizing Collaboration between Commercial and Medical Affairs
We define commercialization in the biopharma space as a mindset that requires the entire organization to begin with the patient in mind and build an ethos and structure that ensures all aspects of the company are aligned. The purpose, overall, is to make sure the innovative treatment in development reaches the patient population where it will make… Read the full article… |
Survival in Uncertain Times
Like so many seasoned industry professionals, we eagerly seek thought leader perspectives — on the current biopharma industry landscape; the investment strategies purported to be in play; and (of course) the likely true impact of the Inflation Reduction Act in both the near- and mid-term. As leaders in our own domains, it is essential that we hear… Read the full article… |
Optimize Your Congress Planning
Regardless of your company or drug development stage, congress events are critical undertakings; they represent both a substantial opportunity and a significant investment of time and resources. These events provide an occasion to engage with a wide range of HCPs (including KOLs) to introduce new products, present data, gather insights, and more. Depending on your… Read the full article… |
Communicating Without a Communications Leader
Many of our clients are emerging companies striving towards their first clinical development program in anticipation of delivering on a promise to the patients they hope to serve. In most of these companies, leadership is appropriately focused on advancing the science and developing a “reason to believe” for both internal and external stakeholders (investigators, potential… Read the full article… |
It’s Not All About the Numbers
What is the difference between strategic thinking in quantifying the future and Excel gymnastics? This was a distinction I needed to learn in my early years of marketing and, more specifically, market research. Often, I possessed a rich bevy of insights from primary market research (think green and white-striped cross-tabulations on pin-feed computer paper), together… Read the full article… |
Finding Partners: Standing Out in a Field of Many
When biopharma executives or business development leaders think about developing their “partnering story,” the focus is often on the innovation. That’s understandable. These are science-based organizations, and without question, the innovation is fundamental to the work. However, paying too much attention to the science at the expense of other aspects of the opportunity can lead… Read the full article… |
Gaining Participation in Clinical Trials
When it comes to patient recruitment and retention for clinical trials, the bottom line is simply this: It is important and challenging in all scenarios… the difference is in how significant the focus and effort will need to be. As this article suggests, identifying, engaging, and retaining appropriate patients for clinical trials can be extremely… Read the full article… |